SCHEMBL679191

SCHEMBL679191

Cc1cc(Oc2ccc(Br)cc2F)c(F)cc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGS2 P35354 4/20 0.38
PTGS1 P23219 1/20 0.38
TSHR P16473 2/20 0.37
SLC6A4 P31645 1/20 0.35
DGAT1 O75907 1/20 0.35
NSD2 O96028 1/20 0.34
NSD3 Q9BZ95 1/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
POLB P06746 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27266032 0.82 MAPK1 (0.58) MAPK1L3MBTL1ALDH1A1TDP1PTGS2
SCHEMBL22167335 0.78 MAPK1 (0.42) MAPK1L3MBTL1ALDH1A1TDP1PTGS2
SCHEMBL2443815 0.78 EPAS1 (0.48) ALDH1A1SLC6A4
SCHEMBL20155430 0.77 TRPA1 (0.45) ALDH1A1SLC6A4MEN1KMT2A
SCHEMBL680217 0.76 HSPB1 (0.47) L3MBTL1ALDH1A1TDP1PTGS2PTGS1
SCHEMBL10537325 0.75 MAPK1 (0.40) MAPK1L3MBTL1ALDH1A1TDP1PTGS2
SCHEMBL28509222 0.75 SLC6A2 (0.44) L3MBTL1ALDH1A1PTGS2PTGS1SLC6A4
SCHEMBL30194332 0.75 SLC6A2 (0.44) L3MBTL1ALDH1A1PTGS2PTGS1SLC6A4
SCHEMBL20160290 0.75 EPAS1 (0.44) MAPK1L3MBTL1ALDH1A1TDP1TSHR
SCHEMBL16792756 0.75 CYP1A2 (0.45) L3MBTL1ALDH1A1TSHRSLC6A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
CN-102105462-A Amidophenoxyindazoles useful as inhibitors of C-MET LILLY CO ELI 2011-06-22 CN disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MAPK1 2143/4885L3MBTL1 461/4885ALDH1A1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.